Welcome to our dedicated page for iRhythm Holdings news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Holdings stock.
iRhythm Technologies, Inc. (NASDAQ: IRTC) generates frequent news as a digital health care company focused on long-term ambulatory cardiac monitoring and data-driven arrhythmia detection. News coverage commonly highlights clinical study results, financial performance, product-related updates for the Zio long-term continuous monitoring (LTCM) service, and the company’s participation in major medical and investor conferences.
Many announcements center on real-world evidence and clinical research. iRhythm regularly reports data from large-scale analyses and trials such as CAMELOT, AVALON, AMALFI, and studies presented at the American Heart Association Scientific Sessions, the Asia Pacific Heart Rhythm Society meetings, and other scientific forums. These updates often explore topics like diagnostic yield compared with other monitoring modalities, performance in diverse patient populations, home-based self-application of Zio devices, and earlier arrhythmia detection in at-risk groups, including those with cardio-kidney-metabolic or chronic kidney disease profiles.
Investors and clinicians following IRTC news will also find quarterly earnings releases, guidance updates, and commentary on operational trends in the company’s core Zio LTCM business, mobile cardiac telemetry initiatives, and international expansion. Additional items include information on investor presentations at healthcare conferences and updates on corporate policies or governance disclosed through press releases linked to SEC filings.
This news page aggregates these developments in one place, allowing readers to review iRhythm’s latest clinical evidence, business updates, and strategic commentary over time. For those tracking digital health, ambulatory ECG monitoring, and AI-enabled cardiac diagnostics, the IRTC news feed provides ongoing insight into how the company presents its technology, research findings, and market priorities.
iRhythm Technologies has appointed Karen Ling to its Board of Directors as a Class 1 Director, effective November 1, 2021, while Raymond Scott will retire from the Board on the same date after serving since 2013. Quentin Blackford, iRhythm’s President and CEO, highlighted Ms. Ling's extensive HR leadership experience in healthcare and insurance, which will aid in scaling the company's operations globally. Ms. Ling previously held significant HR roles at AIG and Allergan, and expressed her commitment to contribute to iRhythm's growth and market opportunities.
iRhythm Technologies announced results from the mHealth Screening to Prevent Strokes (mSToPS) study, published in PLOS One. The trial involved 1,718 participants who used the Zio XT monitor vs. 3,371 controls, showing a reduction in serious cardiac events like death and stroke. The actively monitored group had a 3.6 incidence rate per 100 person-years, compared to 4.5 in controls, indicating Zio's effectiveness in detecting atrial fibrillation (AF). The study supports the need for enhanced cardiac screening to prevent adverse outcomes.
iRhythm Technologies announced the appointment of Quentin Blackford as President and CEO effective October 4, 2021. Blackford, previously Chief Operating Officer at Dexcom, brings over 20 years of experience in innovative medical devices and digital health. His leadership is expected to drive iRhythm's growth and market expansion. The company focuses on improving cardiac arrhythmia diagnoses through advanced technology. Douglas Devine will continue as Interim CEO until Blackford assumes his role.
iRhythm Technologies (NASDAQ: IRTC) will participate in the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021, at 5:00 p.m. Eastern Time. The event will feature a presentation by iRhythm's management, accessible via a live and archived webcast on their website. iRhythm is transforming cardiac arrhythmia diagnosis with wearable biosensors and advanced data analytics, improving patient care management. For more information, visit www.irhythmtech.com.
iRhythm Technologies reported a 59.8% increase in revenue for Q2 2021, reaching $81.3 million compared to $50.9 million in Q2 2020. Despite strong demand for the Zio platform, gross margin declined to 68.0% from 69.6% due to lower Medicare reimbursement rates and increased overtime costs. Operating expenses rose to $72.3 million, causing a net loss of $17.4 million, an improvement from last year's $20.4 million. For 2021, revenue guidance is set at $320-$325 million, reflecting 21%-23% growth.
iRhythm Technologies (NASDAQ: IRTC), a leader in digital healthcare for cardiac care, will participate in the 41st Annual Canaccord Genuity Global Growth Conference on August 12, 2021, at 1:00 p.m. ET. The event will highlight the company’s innovative approach to diagnosing cardiac arrhythmias using wearable biosensor devices and cloud-based data analytics. Interested parties can access the live and archived webcast on the company website.
iRhythm Technologies, Inc. (NASDAQ: IRTC) will report its Q2 2021 financial results on August 5, 2021, after market close. A conference call, starting at 1:30 p.m. PT / 4:30 p.m. ET, will accompany the results. The company specializes in digital health care solutions for cardiac care, utilizing advanced biosensor devices and cloud-based analytics for arrhythmia diagnosis. This innovative approach aims to significantly enhance patient management by providing actionable insights from extensive cardiac data.
iRhythm Technologies (NASDAQ: IRTC) commented on the CMS 2022 Medicare Physician Fee Schedule Proposed Rule released on July 13, 2021. The rule outlines payment policies for long-term continuous ECG monitoring, which is critical for iRhythm's Zio XT service. CMS has not proposed national rates and will continue contractor pricing for specific CPT codes. iRhythm plans to engage in the public comment period and collaborate with MACs for potential local pricing. The final rule is expected by early November 2021, with implementation on January 1, 2022.
iRhythm Technologies (NASDAQ: IRTC) has announced a partnership with the National Association of Managed Care Physicians (NAMCP) to enhance the assessment of long-term continuous cardiac monitoring for managed care organizations. With a focus on value-based medicine, the collaboration aims to establish standards for evaluating these technologies' impact on patient outcomes, experiences, clinician experiences, and care costs. iRhythm emphasizes its leadership in the cardiac monitoring sector, with significant data backing its innovative AI solutions, which are crucial for healthcare providers adapting to the challenges of a post-COVID-19 landscape.
iRhythm Technologies (NASDAQ: IRTC) announced that Michael Coyle has stepped down as President and CEO due to personal matters, effective June 1, 2021. Douglas Devine, the Chief Financial Officer, will serve as interim CEO while a search for a permanent replacement is conducted. The Board has retained an executive search firm for this purpose. iRhythm expects the leadership change will not affect ongoing reimbursement discussions concerning its Zio XT technology. The company maintains its second quarter 2021 guidance, projecting approximately 4% sequential volume growth and flat operating expenses compared to Q1 2021.